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Cardiovascular co-morbidity in cancer
patients: the role of psychological distress
Dounya Schoormans1*, Susanne S. Pedersen2,3, Susanne Dalton4, Nina Rottmann2,5
and Lonneke van de Poll-Franse1,6,7
Abstract
Due to aging of the population and cardiotoxic cancer treatment, there is an increasing group of patients with
cancer and co-morbid cardiovascular disease (CVD). In order to find a balance between the risk of undertreating
the malignancy on the one hand and inducing CVD on the other hand, CVD risk stratification at the time of cancer
diagnosis and knowledge on the pathway for developing incident CVD in cancer patients is vital. In this paper, we
propose an adapted multiple-hit hypothesis for developing CVD in cancer patients describing that patients with
cancer are exposed to a series of sequential or concurrent events that together make them more vulnerable to
reduced cardiovascular reserves, development of incident CVD and ultimately death. We highlight the possible
impact of psychological distress secondary to a cancer diagnosis and/or treatment, which in turn may increase
the risk of incident CVD in patients diagnosed with cancer. Furthermore, we discuss potential behavioral and
pathophysiological mechanisms underlying the link between psychological distress and the pathophysiology of
incident CVD. In addition, key unanswered questions for future research are posed. In the future, researching the
adapted multiple-hit hypothesis for developing CVD among cancer patients will hopefully advance the care of
cancer patients by finding some of the missing pieces of the puzzle. To do so, we need to focus on minimizing
cardiovascular risk and promoting cardiovascular health in cancer patients by addressing the knowledge gaps
formulated in this paper.
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Cardiovascular co-morbidity in cancer patients
Due to aging of the population, there is an increasing
number of patients with cancer and co-morbid cardiovas-
cular disease (CVD). Additionally, cancer patients may
develop incident CVD as a result of the cardiotoxicity of
cancer treatment. Fortunately, there has been increasing
awareness of co-morbid CVD in cancer patients. In 2009,
the International CardiOncology Society (ICOS) was
established [1]. ICOS advocates a multi-disciplinary effort
to combat CVD in cancer patients by both training
oncologists and cardiologists and conducting multidis-
ciplinary research. In 2014, during the international collo-
quium on cardio-oncology, ICOS stressed the importance
of finding a balance between the risk of undertreating the
malignancy on the one hand and inducing CVD by over-
treating on the other hand [2]. In order to accomplish this
goal, they emphasize the importance of CVD risk stratifi-
cation at the time of cancer diagnosis. Recommendations
based on consensus have also been published to target the
vulnerable cancer patient population, emphasizing the im-
portance of a thorough cardiac evaluation, including the
assessment of risk factors, prior to formulating a cancer
treatment plan [3].
Adapted multiple-hit hypothesis: the impact of
psychological distress
Important in CVD risk stratification is knowledge of the
pathway for developing CVD in cancer patients. Within
the field of cardio-oncology there is increasing interest in
the multiple-hit hypothesis for developing CVD in cancer
patients. This hypothesis was first described by Jones et al.
in 2007 [4], and proposes that patients with cancer are
exposed to a series of sequential or concurrent events that
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together make them more vulnerable to reduced car-
diovascular reserves, development of incident CVD and
ultimately death. With new developments in the field of
cardio-oncology and by including knowledge on psy-
chological distress as a risk factor for the pathogenesis
of CVD in non-cancer populations, we have adapted
the multiple-hit hypothesis (Fig. 1). In this paper, we
will describe the adapted hypothesis in more detail, fo-
cusing on psychological distress secondary to a cancer
diagnosis and/or treatment, which in turn may increase
the risk of incident CVD in patients diagnosed with
cancer. In the model, depicted arrows represent the
most dominant associations, although many other rela-
tions exist. It should be noted that the current model
depicted in Fig. 1 is a necessary simplification as vari-
ous factors are associated with one another. To main-
tain comprehensibility of the model, not all associations
will be explicitly depicted in the model, yet many of
these associations are addressed throughout the paper.
Cancer treatment (a)
Cancer treatment consists of radiation, chemo-, hormone,
targeted-, or immunotherapy or a combination of those.
Some of these cancer treatments are cardiotoxic.
Chemotherapy with anthracyclines as well as radiation
to the chest in treating lymphomas or breast cancer are
two examples of cardiotoxic cancer treatments [5, 6].
These cardiotoxic treatments can lead to reduced cardio-
vascular reserves and ultimately a heterogeneous group of
CVDs ranging from benign to potentially lethal, repre-
sented by the unidirectional arrow ‘a’ (Fig. 1) [7, 8]. CVDs
that have been associated with cancer treatments include
thrombosis, electrocardiographic changes, arrhythmias,
myopericarditis, myocardial infarction, cardiomyopathy,
valvular heart disease, and congestive heart failure [5, 6].
These CVDs can occur within days, weeks, months or
years after treatment [5]. Some CVDs are relatively
treatment-specific. For example, heart failure is common
as a sequel to treatment with anthracyclines [6], whereas
thoracic radiation to the left side of the chest involving the
heart has been associated with risk of valvular stenosis,
restrictive cardiomyopathy, pericarditis, and myocardial
infarction post treatment [7].
CVD risk factors (b)
We view the relation between cancer treatment and CVD
risk factors as bidirectional (arrow b1), with CVD risk
factors leading to decreased cardiovascular reserves, CVD
and mortality (unidirectional arrow b2). Having one or
more CVD risk factors, such as older age and morbidities
like hypertension or diabetes mellitus [9] prior to cancer
diagnosis, affect cancer treatment options, often resulting
in the use of less aggressive cancer treatment [10]. We
believe that in light of the multiple-hit hypothesis, the
presence of CVD risk factors may also be viewed as sec-
ondary to cancer treatment: Cancer treatments can induce
CVD risk factors such as hypertension [11] and diabetes
mellitus [12], decreasing cancer patients’ cardiovascular
reserve and enhancing their risk of incident CVD and
mortality. Additionally the effect of CVD risk factors may
be enhanced or diminished by lifestyle factors such as
impaired or increased physical activity or psychological
distress like depressive symptoms (these associations are
not depicted in the model). The direct effects of both life-
style factors and psychological distress on the pathogen-
esis of CVD in cancer patients will be discussed below.
Lifestyle factors (c)
Due to cancer and the intense nature of its treatment, pa-
tients may develop unhealthy lifestyles, including weight
loss and physical inactivity, which may decrease their car-
diac reserve and enhance their risk of CVD and mortality
(depicted by the unidirectional arrows c1 and c2).
Fig. 1 The adapted multiple-hit hypothesis on the pathogenesis of decreased cardiovascular reserve, higher CVD risk, and mortality among cancer
patients. Note: Please note that the current model is a necessary simplification as various factors are associated with one another. To maintain the
comprehensibility of the model, not all associations are explicitly depicted in the model. Interrupted arrows indicate relationships added to the
original model, whereas the uninterrupted arrows describe the original relations or highlight the increasingly acknowledged associations. Please
note, that both bidirectional and unidirectional (causal) arrows are depicted
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Psychological distress (d)
Research on risk factors for the development and progres-
sion of CVD among non-cancer populations has shown
that next to CVD risk factors like hypertension, the mere
presence of psychological distress is bad for patients’
health outcomes. Symptoms of depression, anxiety, spe-
cific personality traits, and fatigue have all been shown to
predict the onset of CVD and the prognosis in patients
with established CVD, independent of traditional biomed-
ical risk factors [13–21]. A recent meta-analysis based on
20 studies examining the predictive value of anxiety for
the incidence of coronary heart disease in originally
healthy individuals found that anxious people had a 26%
increased risk of developing coronary heart disease and a
48% increased risk of cardiac death [14]. The so-called
Type D (‘distressed’) personality has been consistently as-
sociated with poor outcomes in CVD-patients, as indi-
cated in a recent meta-analysis [15]. Individuals with a
Type D personality are characterized by a high score on
both negative affectivity and social inhibition. Negative
affect is the tendency to experience negative emotions,
whereas social inhibition is the tendency to inhibit emo-
tions and to experience a high level of insecurity in social
encounters [22]. Also fatigue is predictive of new onset
CVD in healthy individuals [16, 17] and coronary artery
disease in CVD patients [18]. The psychosocial risk factor
that has been studied the most is depression, with evi-
dence pointing to a relation between depression and the
development of new onset CVDs, such as heart failure
[19, 20], increased risk of major adverse cardiac events
[20, 21], and cardiac death in patients with established
CVD [19].
It is well-known that suffering from cancer and add-
itionally undergoing cancer treatment has a major impact
on patients’ lives, with the majority of cancer patients ex-
periencing psychological problems, such as feelings of
anxiety, fatigue and depression [23, 24]. Moreover, one in
5 cancer patients have a Type D personality [25]. Hence,
cancer patients may have an increased risk for onset CVD
by these elevated levels of psychological distress after
cancer diagnosis alone. It is important to note, however,
that psychological distress could also be present prior to
cancer diagnosis or throughout cancer treatment. Hence,
some individuals may have already been at risk of de-
veloping CVD prior to being diagnosed or treated for
cancer due to their prior experienced level of distress.
In 2007, when the original multiple-hit hypothesis
was proposed, little was known about the potential
putative role of psychological factors in CVD. Only in
2012, the European Society of Cardiology included psy-
chosocial risk factors (e.g. depression and anxiety) in
the Guidelines on Cardiovascular Disease Prevention in
Clinical Practice for the first time [26]. In 2014, the
American Heart Association followed with a Scientific
Statement advocating that depression be given risk fac-
tor status at the same level as traditional risk factors,
due to considerable evidence that depression is linked
not only to CVD prognosis but also that depression is a
risk factor for incident CVD [27]. More recent evidence
implicating psychological distress as a risk factor for
CVD and the fact that cancer patients experience high
levels of psychological distress has inspired us to adapt
the current multiple-hit hypothesis. In addition to includ-
ing the causal effect of cancer diagnosis and treatment on
experiencing psychological distress (unidirectional arrows
d1a and d1b), we added the bidirectional relation between
psychological distress and decreased cardiovascular re-
serve, CVD and mortality (bidirectional arrow d2), as psy-
chological distress is not only a risk factor for incident
CVD but is also increased in cancer patients who have co-
morbid CVD.
Behavioral and pathophysiological mechanisms involved
in psychological distress as a risk factor
The literature on the role of psychological distress in the
pathogenesis of CVD among non-cancer populations has
suggested that various mechanisms - both of behavioral
and pathophysiological nature - are involved. With respect
to behavioral mechanisms, anxiety, Type D personality,
and depression have been related to unhealthy lifestyles,
such as smoking, poor treatment adherence and bad con-
sultation behavior [28–34]. Alternatively, lifestyle factors
such as increased physical activity have been associated
with lower levels of psychological distress, such as symp-
toms of depression [35].
With respect to pathophysiological mechanisms, platelet
dysfunction, autonomic nervous system dysregulation,
hypothalamic-pituitary-adrenal-axis (HPA-axis) dysregula-
tion, cellular ageing, and inflammatory activation have
been suggested to be involved in the relation between
psychological risk factors and CVDs. Platelet activation is
increased in patients with depression [36]. Furthermore,
thrombus formation on the surface of coronary plaque is
key in acute coronary events, making platelet dysfunction
a plausible mechanism [37]. In addition, patients with feel-
ings of anxiety, depression, fatigue and a Type D personal-
ity have reduced heart rate variability (HRV) [38–41],
which is an indicator of cardiac autonomic control
and predictive of cardiovascular morbidity and mortality
[42, 43]. Furthermore, the HPA-axis is known to play a
role in CVD [44]. This system is vital for the regulation of
the physiological reaction to stress, via the hormone corti-
sol, among others. Depressed, anxious, fatigued and Type
D patients show elevated cortisol levels [44–47], suggest-
ing that HPA-axis dysregulation is a possible mechanism.
Likewise, anxiety and depression are related to shorter
telomere length [48–50], a biomarker of cellular aging,
which is in turn involved in the pathogenesis of CVD [51].
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Finally, depression, anxiety, fatigue, and Type D personal-
ity have been associated with elevated levels of pro-
inflammatory cytokines (e.g. interleukin-1 (IL), IL-6, TNF-
alpha, and its soluble receptors sTNFR1 and sTNFR2)
[52–55]. In turn, these cytokines are involved in the
pathogenesis of CVDs, such as heart failure [56].
Research agenda to study the adapted multiple-hit
hypothesis
To date, there is limited research on the multiple-hit
hypothesis for the development of CVD in cancer
patients. Hence, there is an urgent need for research on
the impact of psychological distress on incident CVD
among cancer patients and the potentially additive or
synergistic effects of cardiotoxic treatment, CVD risk
factors, lifestyle factors and psychological distress, as
described in the multiple-hit hypothesis. This know-
ledge will aid in risk stratification at the time of cancer
diagnosis in order to (i) determine the appropriate can-
cer therapy and provide individually tailored treatment
to decrease the risk of incident CVD, and (ii) identify
patients at risk of incident CVD who could benefit
from a disease management program to minimize the
impact of CVD risk factors and psychological distress.
For example, when treating a cancer patient with de-
pression one would not only treat the depression but
also reduce CVD risk and thus improve the patient’s
quality of life and general health outcomes. Knowledge
of the underlying behavioral and pathophysiological
mechanisms is essential as it provides insight into un-
derstanding these relations, ultimately providing targets
for intervention. In addition, information on clinical
and patient-reported outcomes of cancer patients with
co-morbid CVD will help tailor future care for this vul-
nerable patient group.
To answer these questions we can use various data
sources, such as: (a) newly developed longitudinal in-
depth data collections; (b) large population-based longitu-
dinal aging studies; and (c) existing databases. Ideally,
newly developed longitudinal in-depth data collections
with long-term follow-up should be initiated, enabling a
sufficient number of CVD events to occur. These studies
should include information on all the aspects described in
the multiple-hit hypothesis (i.e., type of cancer treatment,
CVD risk factors, lifestyle factors, psychological distress,
cardiovascular reserves, co-morbid CVD and mortality).
Moreover, information on pathophysiological mecha-
nisms, such as markers of inflammation or cellular aging,
should be collected to gain insight into underlying mecha-
nisms. By following oncology patients, one could examine
the specific cardiotoxic effects and their interaction with
CVD risk factors, lifestyle factors and psychological
distress. Furthermore, large population-based longitudinal
aging studies including originally healthy individuals
would enable the identification of risk factors common to
both cancer and CVD. It would also allow the examin-
ation of CVD risk factors present prior to a cancer diagno-
sis as healthy non-cancer patients would be included and
followed over time until they first develop cancer and then
pose the risk of developing CVD. These healthy individ-
uals moreover offer matched cancer-free controls for each
cancer patient as a reference group. Existing databases
also offer unique opportunities to study parts of the re-
search questions that can be extracted from our adapted
multiple-hit hypothesis. For example, in the Netherlands,
information from the southern region Netherlands Cancer
Registry is linked to the PHARMO database network [57].
The population-based Netherlands Cancer Registry in-
cludes clinical information on type of malignancy, date of
diagnosis and type of primary cancer treatment for all
newly diagnosed cancer patients in the Netherlands. The
PHARMO database is a network of electronic healthcare
databases and combines data from primary and secondary
healthcare settings in the Netherlands. Information on
hospitalizations and drug dispensing records from the
PHARMO database can be used to determine whether
someone has co-morbid CVD, CVD risk factors (e.g.
hypertension) or have a severe mental condition (e.g. clin-
ical depression). These linked databases enable us to
examine associations between cardiotoxic cancer treat-
ment, CVD risk factors and psychological distress and
their effect on the development of co-morbid CVD.
In conclusion, by researching the adapted multiple-hit
hypothesis for developing CVD among cancer patients,
we hope to find some of the missing pieces of the puzzle.
Our ultimate goal is to advance the care of cancer pa-
tients. Therefore, we need to focus on the minimization of
cardiovascular risk and promotion of cardiovascular health
in cancer patients by addressing the knowledge gaps, as
formulated above.
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